Article Information
History
- August 30, 2022.
Article Versions
- Version 1 (August 21, 2022 - 09:48).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Thomas R. Moench1,*,
- Lakshmi Botta1,
- Brian Farrer1,
- Jason D. Lickliter2,
- Hyunah Kang3,
- Yoona Park3,
- Cheolmin Kim3,
- Marshall Hoke1,
- Miles Brennan1,
- Morgan D. McSweeney1,
- Zachary Richardson1,
- John B. Whelan1,
- Jong Moon Cho3,
- Soo Young Lee3,
- Frances Faurot1,
- Jeff Hutchins1 and
- Samuel K. Lai1,4,*
- 1Inhalon Biopharma, Inc., 5151 McCrimmon Parkway, Suite 220, Research Triangle Park, Morrisville, NC 27560
- 2Nucleus Network Pty Ltd, Level 5 Burnet Tower, 89 Commercial Road, Melbourne, VIC 3004 Australia
- 3Biotechnology Research Institute, Celltrion Inc, Incheon 22014, Republic of Korea
- 4Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 125 Mason Farm Rd, Chapel Hill, NC 27599
- ↵*Corresponding Author: Thomas R. Moench, moench{at}inhalon.com; Samuel Lai, lai{at}inhalon.com
Author Contributions: TRM, MH, MB, JH and SKL conceptualized and designed the study.
LB, BF, MDM, and ZR performed experiments. BF and JH supervised the experiments.
LB, BF, MDM, JH and SKL contributed to data analysis.
JDL, FF, TRM and JH managed and coordinated the clinical trial execution. JDL was Principal Investigator.
JH, SKL and JBW acquired the financial support.
All authors critically revised the manuscript and approved the submitted version.
The academic authors and the authors who are employees of the sponsor vouch for the accuracy and completeness of the data, the statistical analysis, and the fidelity of the study to the protocol.
Posted August 30, 2022.
A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19
